• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Adolescents, girls more vulnerable to persistent postconcussion symptoms

byMichael DinhandMarc Succi, MD
October 25, 2018
in Chronic Disease, Emergency, Neurology, Pediatrics, Public Health
Reading Time: 2 mins read
Pre-operative transcranial magnetic stimulation useful for language mapping
Share on FacebookShare on TwitterShare on LinkedIn

1. Postconcussion syndromes persisted at 12 months after mild traumatic brain injury (mTBI) in 39% of children.

2. Adolescence, female sex, lower income, preinjury mood problems, and poorer family function were associated with higher severity of chronic postconcussion symptoms during the year after mTBI.

Evidence Rating Level: 2 (Good)

Study Rundown: Mild traumatic brain injury can lead to prolonged cognitive, physical, and affective postconcussion symptoms for many months after the initial injury. Previous literature is inconsistent in identifying factors that predispose children to developing postconcussion symptoms.  In this prospective cohort study, researchers used postconcussion symptom surveys and family function surveys examine persistence of postconcussion symptoms after mTBI. Girls had twice the odds of chronic postconcussion symptoms at 12 months after mTBI when compared to boys. Preinjury mood problems, adolescence, lower income, and poorer family function were independently associated with higher symptom burdens, whereas higher social capital was protective against postconcussion symptoms.

The data were obtained via parent report, which may be subject to bias. Furthermore, subjects were identified only in the emergency setting and may not be representative of all children with mTBI. Nonetheless, the study is strengthened by its prospective, longitudinal cohort design and an injury comparison group. For physicians, these findings highlight the importance of identifying patients at risk for prolonged postconcussion symptoms and intervening early to address those problems. 

Click to read the study, published in Pediatrics

RELATED REPORTS

Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results

Relevant reading: Prognosticators of Persistent Symptoms Following Pediatric Concussion: A Systematic Review

In-Depth [prospective cohort]: Researchers used data from 2 pediatric trauma centers to identify 347 children aged 4 to 15 years who sustained a mTBI or orthopedic injury (OI). (Children with severe psychiatric disorders or developmental delay were excluded from the study.) Parents and guardians of these children were surveyed on sociodemographic and child characteristics. Postconcussion symptoms were assessed at 3, 6, and 12 months after injury using the Postconcussion Symptom Inventory – Parent (PCSI-P). Family function and social capital were calculated using the McMaster Family Assessment Device (FAD).

Girls with mTBI had PCSI-P scores that were 3.4 points (SE: 1.19; p = 0.04) higher for girls than for boys across follow-up and higher odds of chronic postconcussion symptoms at 12 months (aOR: 1.91; 95%CI: 1.05-3.59). Preinjury mood problems, adolescence, lower income, and poorer family function were also independently associated with higher symptom burdens after controlling for other factors. Higher social capital (1-point increase in FAD) reduced odds for chronic postconcussion symptoms at 12 months (aOR: 0.66; 95%CI: 0.50-0.88).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Gene therapy targets Duchenne muscular dystrophy in new trial [PreClinical]

Next Post

Ultrasound guidance may improve rates of successful central venous cannulation

RelatedReports

An illustration showing human lungs, a tray with sampling devices, and a teal awareness ribbon, representing lung cancer diagnostics and lymph node sampling.
2MM Trial Briefs

Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results

October 26, 2026
Illustration showing the lungs with a tumor, a vial representing medication, and surgical tools, indicating lung cancer treatment involving toripalimab.
2MM Trial Briefs

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results

October 25, 2026
An illustration of the pancreas, highlighting cancer cells related to pancreatic cancer and molecular structures, indicating targeted research in oncology.
2MM Trial Briefs

Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial

October 25, 2026
An older woman looks thoughtfully to the side, with dumbbells, running shoes, and a bottle of supplements nearby, suggesting themes of exercise and health in geriatrics.
Chronic Disease

An electronic health record tool for exercise prescription may reduce fall rate among older adults

October 24, 2026
Next Post

Ultrasound guidance may improve rates of successful central venous cannulation

UTI associated with increased risk of preeclampsia

Intensive blood pressure lowering favored to not induce kidney disease, contrary to prior research

High rates of over-diagnosis of pulmonary embolism by CT angiography

Algorithm safely rules out pulmonary embolism in pregnant women

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results
  • Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results
  • Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.